VINC vs. INDP, NERV, NRSN, VBIV, AYTU, TLPH, TRAW, ORGS, VAXX, and APM
Should you be buying Vincerx Pharma stock or one of its competitors? The main competitors of Vincerx Pharma include Indaptus Therapeutics (INDP), Minerva Neurosciences (NERV), NeuroSense Therapeutics (NRSN), VBI Vaccines (VBIV), Aytu BioPharma (AYTU), Talphera (TLPH), Traws Pharma (TRAW), Orgenesis (ORGS), Vaxxinity (VAXX), and Aptorum Group (APM). These companies are all part of the "pharmaceutical preparations" industry.
Indaptus Therapeutics (NASDAQ:INDP) and Vincerx Pharma (NASDAQ:VINC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, community ranking, profitability, risk, media sentiment, earnings and valuation.
Vincerx Pharma received 10 more outperform votes than Indaptus Therapeutics when rated by MarketBeat users. However, 83.33% of users gave Indaptus Therapeutics an outperform vote while only 64.52% of users gave Vincerx Pharma an outperform vote.
7.1% of Indaptus Therapeutics shares are held by institutional investors. Comparatively, 44.0% of Vincerx Pharma shares are held by institutional investors. 27.1% of Indaptus Therapeutics shares are held by insiders. Comparatively, 22.9% of Vincerx Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Vincerx Pharma's return on equity of -108.14% beat Indaptus Therapeutics' return on equity.
Indaptus Therapeutics has a beta of 1.28, meaning that its stock price is 28% more volatile than the S&P 500. Comparatively, Vincerx Pharma has a beta of 1.53, meaning that its stock price is 53% more volatile than the S&P 500.
In the previous week, Vincerx Pharma had 4 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 6 mentions for Vincerx Pharma and 2 mentions for Indaptus Therapeutics. Vincerx Pharma's average media sentiment score of 1.47 beat Indaptus Therapeutics' score of -0.34 indicating that Indaptus Therapeutics is being referred to more favorably in the media.
Indaptus Therapeutics is trading at a lower price-to-earnings ratio than Vincerx Pharma, indicating that it is currently the more affordable of the two stocks.
Indaptus Therapeutics presently has a consensus price target of $12.00, indicating a potential upside of 400.00%. Vincerx Pharma has a consensus price target of $5.00, indicating a potential upside of 594.44%. Given Indaptus Therapeutics' higher probable upside, analysts clearly believe Vincerx Pharma is more favorable than Indaptus Therapeutics.
Summary
Indaptus Therapeutics beats Vincerx Pharma on 7 of the 13 factors compared between the two stocks.
Get Vincerx Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for VINC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VINC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vincerx Pharma Competitors List
Related Companies and Tools
